Eli Lilly and Company (NYSE:LLY) Hits New 52-Week High – Should You Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $1,286.30 and last traded at $1,288.7370, with a volume of 845915 shares changing hands. The stock had previously closed at $1,225.73.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zepbound growth reinforces obesity-market momentum. Sales of Lilly’s Zepbound reportedly increased 46%, supporting expectations for sustained demand for its weight-loss and diabetes treatments. Lilly is also gaining ground on Novo Nordisk in the increasingly competitive market for oral weight-loss pills. Eli Lilly’s Zepbound Sales Jump 46%
• Positive Sentiment: Retatrutide remains a major future catalyst. Reports on favorable trial developments for Lilly’s next-generation obesity candidate have increased expectations for the company’s longer-term growth and helped position Lilly as a leading challenger to Novo Nordisk in weight-loss medicines. Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: Business development is expanding the pipeline. Lilly entered an ion-channel drug-discovery collaboration with OmniAb and paid AlzeCure $10 million upfront for rights related to CNS drug candidates. Lilly is also reportedly among major pharmaceutical companies evaluating a clinical-stage radiopharmaceutical cancer company, highlighting its interest in additional growth platforms. OmniAb Enters Collaboration with Lilly
• Neutral Sentiment: Recent earnings provide a strong foundation. Lilly’s latest quarterly results exceeded consensus estimates, with revenue up 47.7% year over year. Analysts continue to cite GLP-1 demand and the company’s broad pipeline as sources of long-term momentum, while the consensus view remains broadly bullish.
• Negative Sentiment: Competition and valuation could limit further upside. Novo Nordisk’s progress in oral obesity treatments, potential pricing pressure and Lilly’s elevated earnings multiple create execution risks after the stock’s substantial rally.
• Negative Sentiment: An executive sale is a minor headwind. EVP Patrik Jonsson sold 6,500 shares worth approximately $7.6 million, reducing his holdings by 10.72%. Because the trade occurred under a pre-arranged Rule 10b5-1 plan, it is less significant as a discretionary bearish signal. SEC Insider Transaction Filing

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Bank of America boosted their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. Finally, Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company Price Performance

The business’s fifty day moving average price is $1,173.20 and its 200-day moving average price is $1,055.15. The company has a market capitalization of $1.20 trillion, a P/E ratio of 42.59, a P/E/G ratio of 1.39 and a beta of 0.51. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the prior year, the firm earned $6.31 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the business. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. Maseco LLP lifted its stake in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the last quarter. Finally, Aventus Investment Advisors Inc. boosted its holdings in Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after acquiring an additional 27 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.